Skip to main content

Articles

Page 23 of 30

  1. Familial Alzheimer’s disease (FAD) is caused by mutations in the amyloid precursor protein (APP) or presenilin (PS). Most PS mutations, which account for the majority of FAD cases, lead to an increased ratio o...

    Authors: Jean-François Blain, Matthew G. Bursavich, Emily A. Freeman, Lori A. Hrdlicka, Hilliary E. Hodgdon, Ting Chen, Don E. Costa, Bryce A. Harrison, Sudarshan Kapadnis, Deirdre A. Murphy, Scott Nolan, Zhiming Tu, Cuyue Tang, Duane A. Burnett, Holger Patzke and Gerhard Koenig
    Citation: Alzheimer's Research & Therapy 2016 8:34
    Content type: Research Published on:

  2. Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline...

    Authors: Penny A. Dacks, Joshua J. Armstrong, Stephen K. Brannan, Aaron J. Carman, Allan M. Green, M. Sue Kirkman, Lawrence R. Krakoff, Lewis H. Kuller, Lenore J. Launer, Simon Lovestone, Elizabeth Merikle, Peter J. Neumann, Kenneth Rockwood, Diana W. Shineman, Richard G. Stefanacci, Priscilla Velentgas…
    Citation: Alzheimer's Research & Therapy 2016 8:33
    Content type: Review Published on:

  3. The age gap between participants in trials and patients who could benefit from the drugs studied has been widely documented across different clinical areas. Patients with dementia included in clinical research...

    Authors: Rita Banzi, Paolo Camaioni, Mauro Tettamanti, Vittorio Bertele’ and Ugo Lucca
    Citation: Alzheimer's Research & Therapy 2016 8:32
    Content type: Research Published on:

  4. The aim of this volumetric study was to explore the neuroanatomical correlates of the Free and Cued Selective Reminding Test (FCSRT) and the Delayed Matching-to-Sample—48 items (DMS-48), two tests widely used ...

    Authors: N. Philippi, V. Noblet, E. Duron, B. Cretin, C. Boully, I. Wisniewski, M. L. Seux, C. Martin-Hunyadi, E. Chaussade, C. Demuynck, S. Kremer, S. Lehéricy, D. Gounot, J. P. Armspach, O. Hanon and F. Blanc
    Citation: Alzheimer's Research & Therapy 2016 8:26
    Content type: Research Published on:

  5. Current projections of the scale of the coming dementia epidemic assume that the age- and sex-specific prevalence of dementia will not vary over time, and that population ageing alone (increasing the number of...

    Authors: Martin Prince, Gemma-Claire Ali, Maëlenn Guerchet, A. Matthew Prina, Emiliano Albanese and Yu-Tzu Wu
    Citation: Alzheimer's Research & Therapy 2016 8:23
    Content type: Research Published on:

  6. Little is known about the patterns of brain atrophy in prodromal dementia with Lewy bodies (pro-DLB).

    Authors: Frederic Blanc, Sean J. Colloby, Benjamin Cretin, Paulo Loureiro de Sousa, Catherine Demuynck, John T. O’Brien, Catherine Martin-Hunyadi, Ian McKeith, Nathalie Philippi and John-Paul Taylor
    Citation: Alzheimer's Research & Therapy 2016 8:31
    Content type: Research Published on:

  7. We aimed to describe specific changes in brain perfusion in patients with dementia with Lewy bodies (DLB) at both the prodromal (also called mild cognitive impairment) and mild dementia stages, relative to pat...

    Authors: Daniel Roquet, Marion Sourty, Anne Botzung, Jean-Paul Armspach and Frédéric Blanc
    Citation: Alzheimer's Research & Therapy 2016 8:29
    Content type: Research Published on:

  8. Targeted delivery of nerve growth factor (NGF) has emerged as a potential therapy for Alzheimer’s disease (AD) due to its regenerative effects on basal forebrain cholinergic neurons. This hypothesis has been t...

    Authors: Helga Eyjolfsdottir, Maria Eriksdotter, Bengt Linderoth, Göran Lind, Bengt Juliusson, Philip Kusk, Ove Almkvist, Niels Andreasen, Kaj Blennow, Daniel Ferreira, Eric Westman, Inger Nennesmo, Azadeh Karami, Taher Darreh-Shori, Ahmadul Kadir, Agneta Nordberg…
    Citation: Alzheimer's Research & Therapy 2016 8:30
    Content type: Research Published on:

  10. Apolipoprotein E (APOE) ɛ4 and low cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels are predictors for developing Alzheimer’s disease (AD). The results of several studies indicate an interaction between docosa...

    Authors: Hussein N. Yassine, Varun Rawat, Wendy J. Mack, Joseph F. Quinn, Karin Yurko-Mauro, Eileen Bailey-Hall, Paul S. Aisen, Helena C. Chui and Lon S. Schneider
    Citation: Alzheimer's Research & Therapy 2016 8:25
    Content type: Research Published on:

  11. Immunotherapy with monoclonal antibodies that target amyloid beta has been under investigation as a treatment for patients with Alzheimer’s disease (AD). The 3000 and 3001 phase 3 clinical studies of intraveno...

    Authors: Adrian Ivanoiu, Jérémie Pariente, Kevin Booth, Kasia Lobello, Gerald Luscan, Lisa Hua, Prisca Lucas, Scot Styren, Lingfeng Yang, David Li, Ronald S. Black, H. Robert Brashear and Thomas McRae
    Citation: Alzheimer's Research & Therapy 2016 8:24
    Content type: Research Published on:

  12. Affective and psychotic disorders are mental or behavioural patterns resulting in an inability to cope with life’s ordinary demands and routines. These conditions can be a prodromal event of Alzheimer’s diseas...

    Authors: Claire Paquet, Eloi Magnin, David Wallon, Anne-Cécile Troussière, Julien Dumurgier, Alain Jager, Frank Bellivier, Elodie Bouaziz-Amar, Frédéric Blanc, Emilie Beaufils, Carole Miguet-Alfonsi, Muriel Quillard, Susanna Schraen, Florence Pasquier, Didier Hannequin, Philippe Robert…
    Citation: Alzheimer's Research & Therapy 2016 8:27
    Content type: Research Published on:

  13. Increased concentrations of cerebrospinal fluid (CSF) total tau (t-tau) and phosphorylated tau, as well as decreased amyloid-β 42 peptide, are biomarkers of Alzheimer’s disease (AD) pathology, but few studies ...

    Authors: Malin Degerman Gunnarsson, Martin Ingelsson, Kaj Blennow, Hans Basun, Lars Lannfelt and Lena Kilander
    Citation: Alzheimer's Research & Therapy 2016 8:22
    Content type: Research Published on:

  14. A growing body of evidence suggests that microRNAs (miRNAs) are involved in Alzheimer’s disease (AD) and that some disease-associated genetic variants are located within miRNA binding sites. In the present stu...

    Authors: Charlotte Delay, Benjamin Grenier-Boley, Philippe Amouyel, Julie Dumont and Jean-Charles Lambert
    Citation: Alzheimer's Research & Therapy 2016 8:20
    Content type: Research Published on:

  15. Cerebrospinal fluid (CSF) amyloid-beta (Aβ) peptides are predictive biomarkers for Alzheimer’s disease and are proposed as pharmacodynamic markers for amyloid-lowering therapies. However, frequent sampling res...

    Authors: Bianca Van Broeck, Maarten Timmers, Steven Ramael, Jennifer Bogert, Leslie M. Shaw, Marc Mercken, John Slemmon, Luc Van Nueten, Sebastiaan Engelborghs and Johannes Rolf Streffer
    Citation: Alzheimer's Research & Therapy 2016 8:21
    Content type: Research Published on:

  16. Over the past two decades, the APOE gene and its polymorphisms have been among the most studied risk factors of Alzheimer disease (AD) development; yet, there are discrepancies between various studies regarding t...

    Authors: Anna Limon-Sztencel, Beata S. Lipska-Ziętkiewicz, Magdalena Chmara, Bartosz Wasag, Leszek Bidzan, Beata R. Godlewska and Janusz Limon
    Citation: Alzheimer's Research & Therapy 2016 8:19
    Content type: Research Published on:

  17. Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD).

    Authors: Rik Vandenberghe, Juha O. Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens, Bruno Vellas, Michael Tuchman, Achim Gass, Jochen B. Fiebach, Derek Hill, Kasia Lobello, David Li, Tom McRae, Prisca Lucas, Iona Evans, Kevin Booth…
    Citation: Alzheimer's Research & Therapy 2016 8:18
    Content type: Research Published on:

  18. Alzheimer’s disease (AD) neuropathology is associated with neuroinflammation, but there are few useful biomarkers. Mutant variants of triggering receptor expressed on myeloid cells 2 (TREM2) have recently been...

    Authors: Kristi Henjum, Ina S. Almdahl, Vibeke Årskog, Lennart Minthon, Oskar Hansson, Tormod Fladby and Lars N. G. Nilsson
    Citation: Alzheimer's Research & Therapy 2016 8:17
    Content type: Research Published on:

  20. CRTC1 (CREB regulated transcription coactivator 1) gene plays a role in synaptic plasticity, learning and long-term memory formation in the hippocampus. Recently, CRTC1 has been shown ...

    Authors: Maite Mendioroz, Naiara Celarain, Miren Altuna, Javier Sánchez-Ruiz de Gordoa, María Victoria Zelaya, Miren Roldán, Idoya Rubio, Rosa Larumbe, María Elena Erro, Iván Méndez and Carmen Echávarri
    Citation: Alzheimer's Research & Therapy 2016 8:15
    Content type: Research Published on:

  21. Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofi...

    Authors: Veronika Logovinsky, Andrew Satlin, Robert Lai, Chad Swanson, June Kaplow, Gunilla Osswald, Hans Basun and Lars Lannfelt
    Citation: Alzheimer's Research & Therapy 2016 8:14
    Content type: Research Published on:

  22. The purpose of this study was to assess the efficacy of transcranial direct current stimulation (tDCS) on verbal memory function in patients with Alzheimer’s disease.

    Authors: Martin Bystad, Ole Grønli, Ingrid Daae Rasmussen, Nina Gundersen, Lene Nordvang, Henrik Wang-Iversen and Per M. Aslaksen
    Citation: Alzheimer's Research & Therapy 2016 8:13
    Content type: Research Published on:

  23. Theory of mind (ToM) refers to the ability to attribute mental states, thoughts (cognitive component) or feelings (affective component) to others. This function has been studied in man...

    Authors: Camille Heitz, Vincent Noblet, Clélie Phillipps, Benjamin Cretin, Natacha Vogt, Nathalie Philippi, Jennifer Kemp, Xavier de Petigny, Mathias Bilger, Catherine Demuynck, Catherine Martin-Hunyadi, Jean-Paul Armspach and Frédéric Blanc
    Citation: Alzheimer's Research & Therapy 2016 8:10
    Content type: Research Published on:

  24. In Alzheimer’s disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and plaques, a process which is associated with neuronal degeneration, memory loss, and cognitive decline. One therapeu...

    Authors: Mikko Hölttä, Robert A. Dean, Eric Siemers, Kwasi G. Mawuenyega, Wendy Sigurdson, Patrick C. May, David M. Holtzman, Erik Portelius, Henrik Zetterberg, Randall J. Bateman, Kaj Blennow and Johan Gobom
    Citation: Alzheimer's Research & Therapy 2016 8:11
    Content type: Research Published on:

  25. In the First-In-Human (FIH), 39-week, randomized, adaptive design study, safety, tolerability, pharmacokinetics and biomarkers were measured in patients with mild-to-moderate Alzheimer’s disease (AD) after inf...

    Authors: Marielle Delnomdedieu, Sridhar Duvvuri, David Jianjun Li, Nazem Atassi, Ming Lu, H. Robert Brashear, Enchi Liu, Seth Ness and James W. Kupiec
    Citation: Alzheimer's Research & Therapy 2016 8:12
    Content type: Research Published on:

  26. Specific cutoff scores on the Mini Mental State Examination (MMSE) and the Logical Memory (LM) test are used to determine inclusion in Alzheimer’s disease (AD) clinical trials and diagnostic studies. These scr...

    Authors: Kimberly R. Chapman, Hanaan Bing-Canar, Michael L. Alosco, Eric G. Steinberg, Brett Martin, Christine Chaisson, Neil Kowall, Yorghos Tripodis and Robert A. Stern
    Citation: Alzheimer's Research & Therapy 2016 8:9
    Content type: Research Published on:

  27. There is an increasing interest in cognitive and functional outcomes in the respective stages of Alzheimer’s disease (AD) and in novel therapies particularly for the milder phases of AD. Our aim was to describ...

    Authors: Carina Wattmo, Lennart Minthon and Åsa K. Wallin
    Citation: Alzheimer's Research & Therapy 2016 8:7
    Content type: Research Published on:

  28. Development of new treatments for Alzheimer’s disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer’s Dise...

    Authors: Jana Podhorna, Tillmann Krahnke, Michael Shear and John E Harrison
    Citation: Alzheimer's Research & Therapy 2016 8:8
    Content type: Research Published on:

  29. This study was to investigate whether the previously proposed link between Alzheimer’s disease (AD) and decreased retinal nerve fiber layer thickness could be explained by the relationship between abnormal CSF...

    Authors: Eun Ji Lee, Tae-Woo Kim, Dae Seung Lee, Hyunjoong Kim, Young Ho Park, Jungeun Kim, Joon Woo Lee and SangYun Kim
    Citation: Alzheimer's Research & Therapy 2016 8:6
    Content type: Research Published on:

  30. We assessed the impact of retinoid X receptor (RXR) agonist bexarotene on brain amyloid measured by amyloid imaging in patients with Alzheimer’s disease (AD) in a proof-of-concept trial.

    Authors: Jeffrey L. Cummings, Kate Zhong, Jefferson W. Kinney, Chelcie Heaney, Joanne Moll-Tudla, Abhinay Joshi, Michael Pontecorvo, Michael Devous, Anne Tang and James Bena
    Citation: Alzheimer's Research & Therapy 2016 8:4
    Content type: Research Published on:

  31. Alzheimer’s disease is the most frequent age-related dementia, and is currently without treatment. To identify possible targets for early therapeutic intervention we focused on glutamate excitotoxicity, a majo...

    Authors: Abdel G. Elkahloun, Roman Hafko and Juan M. Saavedra
    Citation: Alzheimer's Research & Therapy 2016 8:5
    Content type: Research Published on:

  32. Anxiety in dementia is common but not well studied. We studied the associations of anxiety longitudinally in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB).

    Authors: Monica H. Breitve, Minna J. Hynninen, Kolbjørn Brønnick, Luiza J. Chwiszczuk, Bjørn H. Auestad, Dag Aarsland and Arvid Rongve
    Citation: Alzheimer's Research & Therapy 2016 8:3
    Content type: Research Published on:

  34. Semiquantitative methods such as the standardized uptake value ratio (SUVR) require normalization of the radiotracer activity to a reference tissue to monitor changes in the accumulation of amyloid-β (Aβ) plaq...

    Authors: Sepideh Shokouhi, John W. Mckay, Suzanne L. Baker, Hakmook Kang, Aaron B. Brill, Harry E. Gwirtsman, William R. Riddle, Daniel O. Claassen and Baxter P. Rogers
    Citation: Alzheimer's Research & Therapy 2016 8:2
    Content type: Research Published on:

  35. Electroencephalography (EEG) microstates and brain network are altered in patients with Alzheimer’s disease (AD) and discussed as potential biomarkers for AD. Microstates correspond to defined states of brain ...

    Authors: Florian Hatz, Martin Hardmeier, Nina Benz, Michael Ehrensperger, Ute Gschwandtner, Stephan Rüegg, Christian Schindler, Andreas U. Monsch and Peter Fuhr
    Citation: Alzheimer's Research & Therapy 2015 7:78
    Content type: Research Published on:

  36. The increase in electroencephalogram (EEG) alpha3/alpha2 frequency power ratio has been demonstrated as a biomarker characteristic of subjects with mild cognitive impairment (MCI) who will develop Alzheimer’s ...

    Authors: D. V. Moretti
    Citation: Alzheimer's Research & Therapy 2015 7:80
    Content type: Research Published on:

  37. Studies have shown that proton pump inhibitors (PPIs) increase the brain burden of amyloid-beta (Aβ) and also create vitamin B12 deficiency. However, these two phenomena have deleterious effect on cognition and A...

    Authors: Sanjida Akter, Md. Rajib Hassan, Mohammad Shahriar, Nahia Akter, Md. Golam Abbas and Mohiuddin Ahmed Bhuiyan
    Citation: Alzheimer's Research & Therapy 2015 7:79
    Content type: Research Published on:

  38. Neuroinflammation and synaptic degeneration are major neuropathological hallmarks in Alzheimer’s disease (AD). Neurogranin and YKL-40 in cerebrospinal fluid (CSF) are newly discovered markers indicating synapt...

    Authors: Konstantin Hellwig, Hlin Kvartsberg, Erik Portelius, Ulf Andreasson, Timo Jan Oberstein, Piotr Lewczuk, Kaj Blennow, Johannes Kornhuber, Juan Manuel Maler, Henrik Zetterberg and Philipp Spitzer
    Citation: Alzheimer's Research & Therapy 2015 7:74
    Content type: Research Published on:

  39. Alzheimer’s disease brains are characterized by extracellular plaques containing the aggregated amyloid β42 (Aβ42) peptide and intraneuronal tangles containing hyperphosphorylated tau. Aβ42 is produced by sequent...

    Authors: Simon Sjödin, Kerstin K. A. Andersson, Marc Mercken, Henrik Zetterberg, Herman Borghys, Kaj Blennow and Erik Portelius
    Citation: Alzheimer's Research & Therapy 2015 7:77
    Content type: Research Published on:

  40. In this study of preclinical Alzheimer’s disease (AD) we assessed the added diagnostic value of using cerebrospinal fluid (CSF) Aβ ratios rather than Aβ42 in isolation for detecting individuals who are positiv...

    Authors: Katarzyna Adamczuk, Jolien Schaeverbeke, Hugo M. J. Vanderstichele, Johan Lilja, Natalie Nelissen, Koen Van Laere, Patrick Dupont, Kelly Hilven, Koen Poesen and Rik Vandenberghe
    Citation: Alzheimer's Research & Therapy 2015 7:75
    Content type: Research Published on:

  41. Radioligand imaging is a powerful in vivo method to assess the molecular basis of Alzheimer’s Disease. We therefore aimed to visualize the pathological deposition of fibrillar amyloid-β and neuronal dysfunction i...

    Authors: Ann-Marie Waldron, Cindy Wintmolders, Astrid Bottelbergs, Jonathan B. Kelley, Mark E. Schmidt, Sigrid Stroobants, Xavier Langlois and Steven Staelens
    Citation: Alzheimer's Research & Therapy 2015 7:76
    Content type: Research Published on:

  42. A recent study found a significant increase of ABCA7 loss-of-function variants in Alzheimer’s disease (AD) cases compared to controls. Some variants were located on noncoding regions, but it was demonstrated that...

    Authors: Jorge L. Del-Aguila, Maria Victoria Fernández, Jessica Jimenez, Kathleen Black, Shengmei Ma, Yuetiva Deming, David Carrell, Ben Saef, Bill Howells, John Budde and Carlos Cruchaga
    Citation: Alzheimer's Research & Therapy 2015 7:73
    Content type: Research Published on:

  43. This study aimed to investigate the feasibility of predicting the long–term effects of cholinesterase inhibitors (ChEI) with common clinical neuroimaging parameters of Alzheimer’s disease, including medial tem...

    Authors: Yu-Wen Cheng, Ta-Fu Chen, Ting-Wen Cheng, Ya-Mei Lai, Mau-Sun Hua, Ya-Fang Chen and Ming-Jang Chiu
    Citation: Alzheimer's Research & Therapy 2015 7:72
    Content type: Research Published on:

  44. Cerebrospinal fluid (CSF) biomarkers, although of established utility in the diagnostic evaluation of Alzheimer’s disease (AD), are known to be sensitive to variation based on pre-analytical sample processing....

    Authors: Alan Rembach, Lisbeth A. Evered, Qiao-Xin Li, Tabitha Nash, Lesley Vidaurre, Christopher J. Fowler, Kelly K. Pertile, Rebecca L. Rumble, Brett O. Trounson, Sarah Maher, Francis Mooney, Maree Farrow, Kevin Taddei, Stephanie Rainey-Smith, Simon M. Laws, S. Lance Macaulay…
    Citation: Alzheimer's Research & Therapy 2015 7:71
    Content type: Research Published on:

  45. Alzheimer’s disease is a debilitating condition, and the search for an effective treatment is ongoing. Inflammation, in reaction to amyloid deposition, is thought to accelerate cognitive decline. With tumor ne...

    Authors: Megan E. Roerink, Rob JM Groen, Gerben Franssen, Bianca Lemmers-van de Weem, Otto C. Boerman and Jos WM van der Meer
    Citation: Alzheimer's Research & Therapy 2015 7:70
    Content type: Research Published on:

  46. The potential effects of amalgam fillings on the development of Alzheimer’s disease (AD) are not well understood. The aim of the study was to evaluate the association between dental amalgam fillings and Alzhei...

    Authors: Yi-Hua Sun, Oswald Ndi Nfor, Jing-Yang Huang and Yung-Po Liaw
    Citation: Alzheimer's Research & Therapy 2015 7:65
    Content type: Research Published on:

  47. As currently used, the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) has low sensitivity for measuring Alzheimer’s disease progression in clinical trials. A major reason behind the low sen...

    Authors: Nishant Verma, S. Natasha Beretvas, Belen Pascual, Joseph C. Masdeu and Mia K. Markey
    Citation: Alzheimer's Research & Therapy 2015 7:64
    Content type: Research Published on:

  48. We compared the predictive ability of the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) to diagnose dementia in a community-based study.

    Authors: Jung-Lung Hsu, Yen-Chun Fan, Ya-Li Huang, Jui Wang, Wei-Hung Chen, Hou-Chang Chiu and Chyi-Huey Bai
    Citation: Alzheimer's Research & Therapy 2015 7:69
    Content type: Research Published on:

  49. The definition of “objective cognitive impairment” in current criteria for mild cognitive impairment (MCI) varies considerably between research groups and clinics. This study aims to compare different methods ...

    Authors: Brandy L. Callahan, Joel Ramirez, Courtney Berezuk, Simon Duchesne and Sandra E. Black
    Citation: Alzheimer's Research & Therapy 2015 7:68
    Content type: Research Published on:

  50. There have been recent reports about a decline in dementia incidence, but only little is known about trends in the mortality of patients with dementia. Only the simultaneous analysis of both trends can inform ...

    Authors: Gabriele Doblhammer, Anne Fink, Stephanie Zylla and Frans Willekens
    Citation: Alzheimer's Research & Therapy 2015 7:66
    Content type: Research Published on:
Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193